R
Relmada Therapeutics, Inc. (RLMD)
NCM – Real vaqt narxi. Valyuta: USD
7.45
+0.09 (1.22%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
7.45
+0.09 (1.22%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Relmada Therapeutics, Inc. Qo'shma Shtatlarda klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya NDV-01, gemcitabine va docetaxelning nazorat ostida chiqariladigan intravezikal shaklini ishlab chiqishga qaratilgan bo'lib, u mushak invaziv bo'lmagan siydik pufagi saratonining agressiv shakllari bilan og'rigan bemorlar uchun 2-bosqichli klinik sinovdan o'tmoqda; va Sepranolone, allopregnanolone ning neyrosteroid epimeri, u Prader-Willi sindromi, Tourette sindromi, haddan tashqari titroq va haddan tashqari GABAergik faoliyat bilan bog'liq boshqa kasalliklarni davolash uchun 2b-bosqichga tayyor. Kompaniya Asarina Pharma AB va Trigone bilan kelishuvga ega. Relmada Therapeutics, Inc. 2004 yilda tashkil etilgan va shtab-kvartirasi Florida shtatining Coral Gables shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer of Urology |
| Dr. Richard M. Mangano Ph.D. | Consultant |
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Mr. Paul E. Kelly M.B.A. | COO & Director |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-17 | DEFA14A | ea0273288-04.htm |
| 2026-04-17 | DEF 14A | ea0273288-03.htm |
| 2026-04-07 | CORRESP | filename1.htm |
| 2026-04-06 | PRE 14A | ea0273288-01.htm |
| 2026-04-03 | S-3 | ea0282915-s3_relmada.htm |
| 2026-03-20 | 8-K | ea0282688-8k_relmada.htm |
| 2026-03-19 | 10-K | ea0273255-10k_relmada.htm |
| 2026-03-09 | 8-K | ea0280436-8k_relmada.htm |
| 2025-12-15 | 8-K | ea0269660-8k_relmada.htm |
| 2025-11-13 | 8-K | ea026563001-8k_relmada.htm |